qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.

Sunnybrook Health Sciences Centre

Status and phase: Completed; Early Phase 1

Conditions: Glioblastoma; Hypoxia

Treatments: Drug: Feraheme®

Study type: Interventional

Funder types: Other

Identifiers

NCT02466828

127-2014

Details and patient eligibility

About

Glioblastoma multiforme (GBM) is the most common primary malignant brain neoplasm in adults. Despite recent diagnostic and therapeutic advances, including aggressive surgical resection and chemoradiation, the prognosis of GBM has improved only slightly over the past two decades, with median survival of approximately 15 months. Tumor hypoxia is a feature of GBM that contributes to poor outcome through multiple mechanisms such as 1) overexpression of enzymes that play roles in temozolomide resistance, the main chemotherapeutic agent in GBM and 2) increase expression of cancer stem cells which are more resistant to radiation. Hypoxic tumour regions are associated with higher rates of progression and recurrence.

In this study the investigators will use an advanced MRI technique called qBOLD to non-invasively measure oxygenation in GBM and obtain targeted biopsies. The investigators take advantage of physical characteristics of Ferumoxytol (Feraheme®) which is an iron supplement, and utilize two recent technical advances not previously used in human tumours to quantitatively measure oxygenation in GBM.

Prior knowledge of hypoxia can assist in prognostication and individualization of treatment planning with special focus on hypoxic regions by targeted radiation dose or regimen modulation; consideration of more intensive chemotherapy regimens; more aggressive and targeted surgical resection and closer short-term clinical and imaging follow-ups.

Full description

We propose a study to demonstrate quantitative oxygen saturation estimation in GBM is feasible with qBOLD and it correlates with established histopathological markers of hypoxia and angiogenesis, and targeted intraoperative oxygen measurement.

All patients will undergo surgery as part of their standard treatment. By coregistering the hypoxia map on presurgical MRI we will be able to do the following:

1. Obtain targeted biopsies of the hypoxic areas and none hypoxic areas and correlate them with gold standard marker of tissue hypoxia by immunohistochemistry for hypoxia induced factor-1α (HIF-1α).
2. Draw Volumes of interests (VOI) over areas >0.5-cm3 (amenable to accurate intra-operative O2 measurement) with the lowest and highest oxygen saturation (SO2) values. VOIs will be then imported into the neuronavigation system (Stryker) for targeted placement of clinically approved Licox® oxygen-sensing probe (Integra NeuroSciences).

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adult (>18 year old) patients with newly diagnosed GBM presenting to our centre for surgical management and post-operative chemoradiation
2. Creatinine clearance > 60 ml/minute
3. Able to tolerate an MR scan
4. Capable of providing informed consent.

Exclusion criteria

1. Prior brain surgery or radiation
2. History of liver disease requiring liver MRI (due to accumulation of ferumoxytol in Kupffer cells which can affect liver MRI for up to 3 months)
3. On more than two antihypertensive medications
4. History of allergy or adverse reaction to iron supplements
5. Prior treatment with ferumoxytol
6. Large (>50%) hemorrhagic component in the solid enhancing part of the tumor
7. Need for emergency craniotomy.
8. Pregnant patients
9. Breast feeding
10. Serum ferritin of >800 ng/mL

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Single patient group receiving Feraheme®

Experimental group

Description:

Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent

Treatment:

Drug: Feraheme®